Inspira completes HYLA clinical study, plans for regulatory submission and commercialization.

Inspira Technologies has completed a clinical study for its non-invasive blood sensor, HYLA. The study showed 95-99% accuracy across measured parameters, and the company is now in the final validation and verification stage ahead of regulatory submission. Inspira plans to leverage its proprietary platform and integrate machine learning algorithms to extend the sensor's capabilities, adding critical physiological parameters not available through existing non-invasive monitoring systems.